Radionuclide therapy with iodine-125 and other Auger-electron-emitting radionuclides: Experimental models and clinical applications
Radionuclide therapy with iodine-125 and other Auger-electron-emitting radionuclides: Experimental models and clinical applications
复制标题
DOI：
10.1089/108497803322702833
复制
发表时间：
2003-12-01
影响因子：
3.4
通讯作者：
Mariani, G
中科院分区：
文献类型：
--
作者：
Bodei, L;Kassis, AI;Mariani, G
如果俄歇电子发射器可以放置在细胞内，特别是在靠近核DNA(或核DNA)的地方，那么它就代表着一种有吸引力的癌症治疗贝塔粒子发射器的替代方案。基于对动物肿瘤模型的研究，包括卵巢癌、膀胱癌和脑和脊髓肿瘤的动物模型，其中胸苷类似物5-放射性碘-2‘-脱氧尿苷(*IUdR)已被证明在治疗方面有效，因此假设碘-125和其他俄歇电子发射核素在治疗某些恶性肿瘤方面可能有价值，假设肿瘤细胞对放射性药物的摄取超过正常分裂细胞的摄取。初步的患者研究表明，放射性药物的局部区域给药和肿瘤细胞对其摄取的代谢调节可以部分满足这一要求。研究人员继续寻找能够携带俄歇电子发射体到核DNA的分子，特别是那些具有更高的俄歇电子产额和不同半衰期的放射性核素。
Auger-electron emitters represent an attractive alternative to beta-particle emitters for cancer therapy if they can be placed intracellularly, especially in close proximity to (or within) nuclear DNA. Based on investigations in animal tumor models, including those for ovarian cancer, bladder cancer, and brain and spinal cord tumors, in which the thymidine analog 5-radioiodo-2'-deoxyuridine (*IUdR) has been shown to be therapeutically efficacious, it is hypothesized that iodine-125 and other Auger-electron-emitting radionuclides might be valuable in the treatment of certain malignant diseases, assuming that uptake of the radiopharmaceutical by tumor cells exceeds that by normal dividing cells. Preliminary patient studies have shown that this requirement can be met partially by the locoregional administration of the radiopharmaceutical and metabolic modulation of its uptake by tumor cells. Investigators continue to seek molecules that can carry Auger-electron emitters to nuclear DNA, especially those radionuclides with higher Auger-electron yields and varying half-lives.